GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » E10

LadRx (LADX) E10 : $-200.47 (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

LadRx's adjusted earnings per share data for the three months ended in Dec. 2023 was $-1.910. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-200.47 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 19.00% per year. During the past 5 years, the average E10 Growth Rate was 10.80% per year. During the past 10 years, the average E10 Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of LadRx was 22.00% per year. The lowest was -7.80% per year. And the median was 9.10% per year.

As of today (2024-04-26), LadRx's current stock price is $2.25. LadRx's E10 for the quarter that ended in Dec. 2023 was $-200.47. LadRx's Shiller PE Ratio of today is .


LadRx E10 Historical Data

The historical data trend for LadRx's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx E10 Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -373.74 -377.71 -343.78 -303.87 -200.47

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -303.87 -291.44 -285.33 -261.97 -200.47

Competitive Comparison of LadRx's E10

For the Biotechnology subindustry, LadRx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where LadRx's Shiller PE Ratio falls into.



LadRx E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, LadRx's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.91/129.4194*129.4194
=-1.910

Current CPI (Dec. 2023) = 129.4194.

LadRx Quarterly Data

per share eps CPI Adj_EPS
201403 48.000 99.695 62.312
201406 -168.000 100.560 -216.215
201409 -60.000 100.428 -77.321
201412 -144.000 99.070 -188.114
201503 -186.000 99.621 -241.636
201506 -126.000 100.684 -161.961
201509 -66.000 100.392 -85.084
201512 -210.001 99.792 -272.347
201603 -114.000 100.470 -146.847
201606 -162.000 101.688 -206.179
201609 -80.000 101.861 -101.644
201612 -33.000 101.863 -41.927
201703 -60.000 102.862 -75.491
201706 -60.000 103.349 -75.135
201709 -19.000 104.136 -23.613
201712 -13.000 104.011 -16.176
201803 -15.000 105.290 -18.438
201806 -10.000 106.317 -12.173
201809 -10.000 106.507 -12.151
201812 -7.000 105.998 -8.547
201903 -4.000 107.251 -4.827
201906 -4.000 108.070 -4.790
201909 -4.000 108.329 -4.779
201912 -9.000 108.420 -10.743
202003 -3.000 108.902 -3.565
202006 -4.000 108.767 -4.759
202009 -8.000 109.815 -9.428
202012 -3.000 109.897 -3.533
202103 -4.000 111.754 -4.632
202106 -3.000 114.631 -3.387
202109 -4.000 115.734 -4.473
202112 -24.000 117.630 -26.405
202203 -4.000 121.301 -4.268
202206 -2.250 125.017 -2.329
202209 -2.780 125.227 -2.873
202212 8.650 125.222 8.940
202303 -3.000 127.348 -3.049
202306 6.450 128.729 6.485
202309 -1.650 129.860 -1.644
202312 -1.910 129.419 -1.910

Add all the adjusted EPS together and divide 10 will get our e10.


LadRx  (OTCPK:LADX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


LadRx E10 Related Terms

Thank you for viewing the detailed overview of LadRx's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049